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Abstract
Background: We present a rare case of primary mucosal melanoma of the middle ear imaged with 18F-fluoro-2-deoxy-D-
glucose positron emission tomography/computed tomography (FDG-PET/CT).
Method: Clinical, radiological, intra-operative and histological findings are discussed.
Results: An 88-year-old woman presented with intermittent otorrhoea of the left ear for several months. Otoscopy
revealed a livid protrusion of the tympanic membrane. Melanoma was not suspected initially, but was established on
transmembranous biopsy. Pre-operative 18F-fluoro-2-deoxy-D-glucose positron emission tomography/computed
tomography revealed a mass lesion in the left tympanic cavity with high fluoro-deoxyglucose uptake, as well as an
ipsilateral intraparotid lymph node metastasis. The patient underwent surgical treatment. The diagnosis of melanoma
was confirmed histologically.
Conclusion: In this rare case, clinical, radiological and surgical findings led to the diagnosis of a primary mucosal
melanoma of the middle ear.
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Introduction
The vast majority (95 per cent) of malignant melanoma arises
from melanocytes, the pigment-producing cells located
mainly in the basal layer of the epidermis. However, this
tumour can also arise from melanocytes residing in non-
cutaneous tissues, as is the case for mucosal melanoma.1
The treatment of mucosal melanoma is challenging, and
exact pre-operative staging is crucial. 18F-fluoro-2-deoxy-
D-glucose positron emission tomography/computed tom-
ography (FDG-PET/CT) enables evaluation of the primary
tumour extent as well as the detection of lymph node and
distant metastases, all in one imaging procedure. The suc-
cessful use of this imaging procedure in cases of mucosal
melanoma of the head and neck has been previously
reported.2
We report the first case of a middle-ear melanoma imaged
with FDG-PET/CT.
Case report
An 88-year-old woman presented with intermittent otorrhoea
of the left ear for several months. Otoscopy revealed a livid
protrusion of the tympanic membrane. No suspicious neck
lymph nodes were palpable.
Audiometry showed severe combined hearing loss of the
left ear.
The differential diagnosis at this stage was middle-ear
adenoma, paraganglioma, tympanic meningioma, malignant
tumour and infectious diseases such as tuberculosis.
A transmembranous biopsy was undertaken and the diag-
nosis of melanoma was confirmed histologically.
Computed tomography was performed to evaluate the local
extent of the lesion. This showed a mass lesion within the left
middle ear with obliteration of the mastoid cells and erosion
of the tegmen and skull base. The auricular ossicles were
intact and there was no infiltration of the inner ear. Fluoro-
2-deoxy-D-glucose positron emission tomography/computed
tomography was performed for further staging. This demon-
strated increased FDG uptake (maximum standardized uptake
value (SUVmax)= 5.1) of the mass lesion in the left tympanic
cavity (Figure 1a to 1c). Additionally, there was focal FDG
accumulation in the ipsilateral parotid gland (SUVmax=
9.1) (Figure 1d), suspicious for intraparotid lymph node
metastasis. No distant metastases were visible on FDG-
PET/CT imaging.
The patient underwent subtotal petrosectomy and mela-
noma resection as well as lateral left-sided parotidectomy
and a modified left-sided neck dissection. Intra-operatively,
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the lesion presented as a dark, brittle tumour at the tympanic
orifice of the eustachian tube (Figure 2).
Immunohistological examination of the resected middle-
ear tumour confirmed a mucosal melanoma by immuno-
pathological positivity for S-100 (Figure 3a) and Melan-A
(Figure 3b). The lesion in the parotid gland was confirmed
as a lymph node metastasis.
The patient recovered quickly from surgery.
Four months later, an enlarged, left-sided, level II cervical
lymph node was palpated. Subsequent fine needle aspiration
FIG. 1
(a)–(c) Axial Fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography (FDG-PET/CT) scans showing FDG-active
mass lesion in the left tympanic cavity (arrows). (d) Coronal FDG-PET/CT SCAN showing FDG accumulation in the ipsilateral parotid
gland (arrow).
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cytology revealed a melanoma metastasis. Neck dissection
(level II and III) was performed, but revealed no evidence
of additional lymph node metastases.
Six months after initial presentation, the patient developed
multiple distant metastases in the liver and abdominal lymph
nodes and died.
Discussion
A few case reports of malignant melanoma of the middle ear
have previously been published.3–6 Approximately 1.3 per
cent of all melanomas arise within the mucosal surfaces of
the body, and 55 per cent of these occur in the head and
neck.7
The treatment of mucosal melanomas is challenging. The
only curative treatment is complete resection, but clear surgi-
cal margins are often difficult to obtain and this is considered
to contribute to the poor prognosis.7,8 Some studies suggest
that improved local control could be achieved by post-oper-
ative radiotherapy.8
Malignant melanoma can metastasise to any organ,
and the location of metastases is often unpredictable.
Metastasising melanoma is refractory to chemotherapy in
most cases, although several clinical trials of vaccines and
cytokines are in progress.9 Recent studies suggest a thera-
peutic option involving inhibiting signalling pathways in
tumours with the v-Raf murine sarcoma viral oncogene
homolog B1 gene (BRAF) mutation.10 If distant metastasis
of melanoma occurs then the outcome is poor, with an
average survival of only four to six months.1,11
Of the above-mentioned patients with middle-ear mela-
noma, only half survived longer than eight months after
diagnosis.
Clinical evaluation and conventional imaging modalities
generally underestimate the true extent of malignant mela-
noma. Autopsies of patients with known cutaneous malig-
nant melanoma have revealed a higher prevalence of
metastases than is generally clinically documented.12–14
• This paper reports a rare case of primary mucosal
melanoma of the middle ear, imaged with fluoro-
deoxyglucose positron emission tomography/
computed tomography (FDG-PET/CT)
• In melanoma cases, pre-operative FDG-PET/CT
is a valuable aid to surgical planning and
oncological treatment
• The presented patient underwent subtotal
petrosectomy and melanoma resection plus lateral
left-sided parotidectomy and a modified left-sided
neck dissection
Precise staging of malignant melanoma is essential for early
detection of metastases and initiation of appropriate treat-
ment.11,15 The majority of the available literature suggests
that FDG-PET/CT is the most accurate imaging modality
for the detection of metastases in melanoma patients, due
to the high avidity of FDG for melanoma tumour cells.16–18
Conclusion
Malignant melanoma of the middle ear is a very rare entity.
However, it should be considered in the differential diagnosis
of mucosal tumours. It may mimic other conditions found in
the middle ear, and may produce similar symptoms such as
FIG. 2
Intra-operative view showing a brittle, black and purple tumour at
the tympanic orifice of the Eustachian tube (white arrow). The
stapes (white arrowhead), lateral semicircular canal (black arrow)
and facial nerve (black arrowhead) are also visible.
FIG. 3
Photomicrographs showing tympanic membrane with in situ malig-
nant melanoma, with immunopathological positivity for (a) S-100
and (b) Melan-A.
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hearing loss and otorrhoea. Whenever melanoma is con-
sidered, the patient should undergo FDG-PET/CT to
search for local and distant metastases, which if found may
modify surgical and oncological treatment.
References
1 Markovic SN, Erickson LA, Rao RD, Weenig RH, Pockaj BA,
Bardia A et al. Malignant melanoma in the 21st century, part 1:
epidemiology, risk factors, screening, prevention, and diagnosis.
Mayo Clin Proc 2007;82:364–80
2 Goerres GW, Stoeckli SJ, von Schulthess GK, Steinert HC.
FDG PET for mucosal malignant melanoma of the head and
neck. Laryngoscope 2002;112:381–5
3 McKenna EL Jr, Holmes WF, Harwick R. Primary melanoma of
the middle ear. Laryngoscope 1984;94:1459–60
4 Sherman IW, Swift AC, Haqqani MT. Primary mucosal malig-
nant melanoma of the middle ear. J Laryngol Otol 1991;105:
1061–4
5 Curry JM, Kung BC, Willcox TO Jr. Malignant melanoma of
the middle ear. Otolaryngol Head Neck Surg 2007;136:856–7
6 Uchida M, Matsunami T. Malignant amelanotic melanoma of
the middle ear. Arch Otolaryngol Head Neck Surg 2001;127:
1126–8
7 Patel SG, Prasad ML, Escrig M, Singh B, Shaha AR, Kraus DH
et al. Primary mucosal malignant melanoma of the head and
neck. Head Neck 2002;24:247–57
8 Bradley PJ. Primary malignant mucosal melanoma of the head
and neck. Curr Opin Otolaryngol Head Neck Surg 2006;14:
100–4
9 Thompson JF, Scolyer RA, Kefford RF. Cutaneous melanoma.
Lancet 2005;365:687–701
10 Dhomen N, Marais R. BRAF signaling and targeted therapies in
melanoma. Hematol Oncol Clin North Am 2009;23:529–45, ix
11 Balch CM, Soong SJ, Atkins MB, Buzaid AC, Cascinelli N,
Coit DG et al. An evidence-based staging system for cutaneous
melanoma. CA Cancer J Clin 2004;54:131–49, 82–4
12 Amer MH, Al-Sarraf M, Vaitkevicius VK. Clinical presentation,
natural history and prognostic factors in advanced malignant
melanoma. Surg Gynecol Obstet 1979;149:687–92
13 Sampson JH, Carter JH Jr, Friedman AH, Seigler HF.
Demographics, prognosis, and therapy in 702 patients with
brain metastases from malignant melanoma. J Neurosurg
1998;88:11–20
14 Budman DR, Camacho E, Wittes RE. The current causes of
death in patients with malignant melanoma. Eur J Cancer
1978;14:327–30
15 Balch CM, Buzaid AC, Soong SJ, Atkins MB, Cascinelli N,
Coit DG et al. Final version of the American Joint Committee
on Cancer staging system for cutaneous melanoma. J Clin
Oncol 2001;19:3635–48
16 Friedman KP, Wahl RL. Clinical use of positron emission tom-
ography in the management of cutaneous melanoma. Semin
Nucl Med 2004;34:242–53
17 Reinhardt MJ, Joe AY, Jaeger U, Huber A, Matthies A, Bucerius
J et al. Diagnostic performance of whole body dual modality
18F-FDG PET/CT imaging for N- and M-staging of malignant
melanoma: experience with 250 consecutive patients. J Clin
Oncol 2006;24:1178–87
18 Krug B, Crott R, Lonneux M, Baurain JF, Pirson AS, Vander
Borght T. Role of PET in the initial staging of cutaneous malig-
nant melanoma: systematic review. Radiology 2008;249:
836–44
Address for correspondence:
Dr Martin Huellner,
Department of Nuclear Medicine and Radiology,
Cantonal Hospital Lucerne,
CH-6000 Lucerne, Switzerland
Fax: +41 41 205 4689
E-mail: martin.huellner@ksl.ch
Dr M Huellner takes responsibility for the integrity of the
content of the paper
Competing interests: None declared
CLINICAL RECORD 539
https:/www.cambridge.org/core/terms. https://doi.org/10.1017/S0022215110002872
Downloaded from https:/www.cambridge.org/core. University of Basel Library, on 30 May 2017 at 14:34:39, subject to the Cambridge Core terms of use, available at
